We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fresh Red Blood Cells Transfusions No Better Than Older Ones

By LabMedica International staff writers
Posted on 23 Dec 2019
Red blood-cell transfusions are commonly administered in critically ill children who have illnesses that increase the need for transfusion, such as trauma, cancer chemotherapy, major surgery with significant intraoperative bleeding, and conditions such as sickle cell disease and thalassemia.

Transfusion with red blood cells is the only way to rapidly treat severe anemia that could be life-threatening. More...
Red blood cells are stored in blood banks as red-cell units for up to 42 days. Some studies published over the past few decades have suggested that transfusion with red blood-cell units stored for longer periods might be less beneficial than transfusion with fresher red-cell units.

A large international team of scientists led by critical care staff at Sainte-Justine University Hospital Centre (Montreal, QC, Canada) undertook a randomized trial that recruited patients admitted to pediatric intensive care units in 50 medical centers. The study began in February 2014 and ended in November 2018. In the study there were 1,461 children ranging in age from 3 days to 16 years who were admitted to pediatric intensive care units and were recruited in the USA (29 sites), Canada (10 sites), France (eight sites), Italy (two sites), and Israel (one site); Sainte-Justine University Hospital was the coordinating center in Canada and recruited the greatest number of patients (over 160).

During the course of the study, half of the patients received transfusions with fresh red blood cells stored for seven days or less and half received transfusions with older red cells. The primary outcome measured was the development of new or progressive multiple-organ dysfunction (impairment of one or more organs). The team found that fresh red cells did not reduce the incidence of new or progressive multiple-organ dysfunction or death compared to older red cells and that the outcomes were not significantly different between the two groups. About 20.2% of those who received fresh red cells experienced new or progressive organ dysfunction, while 18.2% of those who received older red cells experienced similar dysfunction.

The study did not examine whether the use of the oldest red cells allowable (more than 35 days) affects outcomes, or whether fresh red cells affect outcomes for children requiring large-volume red cell transfusions. The children in this study received low-volume red cell transfusions. The authors concluded that among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality) compared with standard-issue red blood cells. The study was published on December 10, 2019 in the Journal of the American Medical Association.

Related Links:
Sainte-Justine University Hospital Centre


New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.